Lixte Biotechnology Holdings, Inc. reported that its the recent collaboration with the Netherlands Cancer Institute (NKI) and Stichting Oncode Institute has led to an initial joint patent application covering LB-100 combination therapy with one of several other investigational compounds. Lixte, NKI and Oncode Institute believe that the combination therapy would provide unexpectedly strong synergistic anti-cancer effects in cancer patients. Lixte previously announced its entry into a collaboration with the NKI and Oncode Institute to identify the most promising drugs to be used in combination with Lixte's LB-100 or with one of Lixte's LB-100 analogues to treat a range of cancers, as well as to identify the specific molecular mechanisms underlying the identified combinations.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.35 USD | -0.84% | +3.98% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 5.29M | |
+24.74% | 47.54B | |
-0.47% | 41.96B | |
+47.87% | 41.55B | |
+25.40% | 30.36B | |
+17.96% | 27.61B | |
-4.47% | 28.7B | |
+50.73% | 14.7B | |
+42.56% | 13.51B | |
+1.46% | 12.34B |
- Stock Market
- Equities
- LIXT Stock
- News Lixte Biotechnology Holdings, Inc.
- Lixte Biotechnology Announces Filing of First Patent Application Resulting from Collaboration with the Netherlands Cancer Institute and the Oncode Institute to Identify the Most Promising Drug Combinations for Lead Clinical Compound, LB-100